Aldosterone in Diabetic Nephropathy

• Status: Unknown status
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidad de los Andes, Chile; Universidad Los Andes, Chile
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• Diabetic subjects with maximum ten years after diagnostic

• Diabetic nephropathy with albuminuria

• Normal renal function

• Diastolic disfunction

• Taking a IECA or ARA drug family previously

Exclusion Criteria:

• Diabetics subjects with macroangiopathy

• Acute coronary syndrome in the three months before

• Hyperkalemia > 5.5 mEq/L

• Pregnancy